Clinical Outcomes of Acute Leukemia in Children Less Than 2 Years: Experience from a Tertiary Center in Thailand
Abstract
Objective: This study aimed to examine the prognostic factors and treatment outcomes of patients with acute leukemia aged under 2 years.
Material and methods: The medical records of acute leukemia patients aged under 2 between January 1979 and December 2021 were retrospectively reviewed. The Kaplan-Meier method was used to calculate the event-free survival (EFS) and overall survival (OS) rates. A univariate Cox proportional hazards regression model was used to identify clinical factors associated with poor EFS and OS. A p-value<0.05 was considered statistically significant.
Results: Over the 43-year study period, 137 children with acute leukemia aged under 2 years of age were identified. Of these, 70 (51.1%) had acute lymphoblastic leukemia (ALL) and 67 (48.9%) had acute myeloid leukemia (AML). After induction, 89.1% of ALL patients achieved complete remission, with an induction death rate of 3.2%. The 5-year OS and EFS rates were 46.0% and 41.0%, respectively. After induction, 44.8% of the AML patients achieved complete remission, with an induction death rate of 29.3%. The 5-year OS and EFS rates in this group were 10.0% and 9.0%, respectively. No significant prognostic factors were identified to predict survival outcomes in children with AML under 2 years.
Conclusion: Both ALL and AML childhood leukemia patients aged under 2 years had poor survival outcomes.
Keywords
Full Text:
PDFReferences
Silverman LB. Acute lymphoblastic leukemia in infancy. Pediatr Blood Cancer 2007;49:1070–3.
Möricke A, Zimmermann M, Reiter A, Gadner H, Odenwald E, Harbott J, et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the Trials ALL-BFM 86, 90, and 95. Klin Padiatr 2005;217:310–20.
Pieters R, De Lorenzo P, Ancliffe P, Aversa LA, Brethon B, Biondi A, et al. Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 Protocol: results from an international phase III randomized study. J Clin Oncol 2019;37:2246–56.
Cherungonath A, Appaji L, Padma M, Arunakumari B, Arunkumar A, Avinash T, et al. Profile of acute lymphoblastic leukemia in children under 2 years of age. Indian J Med Paediatr Oncol 2018;39:307–11.
Tomizawa D, Koh K, Sato T, Kinukawa N, Morimoto A, Isoyama K, et al. Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 2007;21:2258–63.
Blais S, Boutroux H, Pasquet M, Leblanc T, Fenneteau O, Gandemer V, et al. Is acute myeloblastic leukemia in children under 2 years of age a specific entity? A report from the FRENCH ELAM02 Study Group. HemaSphere 2019;3:e316.
Teyssier AC, Lapillonne H, Pasquet M, Ballerini P, Baruchel A, Ducassou S, et al. Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. Pediatr Hematol Oncol 2017;34:425–7.
Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012;120:3187–205.
Creutzig U, Zimmermann M, Bourquin JP, Dworzak MN, Kremens B, Lehrnbecher T, et al. Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia 2012;26:654–61.
Koren G, Schechter T. Cancer chemotherapy in young children: challenges and solutions. Pediatr Blood Cancer 2007;49:1091–2.
Leiper AD, Chessells J. Acute lymphoblastic leukaemia under 2 years. Arch Dis Child 1986;61:1007–12.
Ibagy A, Silva DB, Seiben J, Winneshoffer APFF, Costa TEJB, Dacoregio JS, et al. Acute lymphoblastic leukemia in infants: 20 years of experience. J Pediatr (Rio J) 2013;89:64–9.
Pui CH, Raimondi S, Srivastava D, Tong X, Behm F, Razzouk B, et al. Prognostic factors in infants with acute myeloid leukemia. Leukemia 2000;14:684-7.
Calvo C, Fenneteau O, Leverger G, Petit A, Baruchel A, Méchinaud F. Infant Acute myeloid leukemia: a unique clinical and biological entity. Cancers (Basel) 2021;13:777.
Aur RJ, Simone J, Hustu HO, Walters T, Borella L, Pratt C, et al. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. Blood 1971;37:272–81.
Gaynon PS, Bleyer WA, Albo VC, Grossman NJ, Novak LT, Reaman GH, et al. Intensive therapy for children with acute lymphoblastic leukaemia and unfavorable presenting features. Lancet 1988;22;2:921–4.
Bleyer WA, Sather H, Coccia P, Lukens J, Siegel S, Hammond GD. The staging of childhood acute lymphoblastic leukemia: strategies of the Childrens Cancer Study Group and a three-dimensional technic of multivariate analysis. Med Pediatr Oncol 1986;14:271–80.
Lauer S, Shuster J, Mahoney D, Winick N, Toledano S, Munoz L, et al. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. Leukemia 2001;15:1038–45.
Tubergen DG, Gilchrist GS, O’Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a childrens cancer group phase III trial. J Clin Oncol 1993;11:527–37.
Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children’s Oncology Group. J Clin Oncol 2012;30:1663–9.
Scheer U, Schellong G, Riehm H. Prognosis improvements in children with acute myelocytic leucemia after more intensive induction therapy. Klin Padiatr 1979;191:210–6.
Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. Blood 1990;75:1932–40.
Creutzig U, Zimmermann M, Lehrnbecher T, Graf N, Hermann J, Niemeyer CM, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006;24:4499–506.
Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531. J Clin Oncol 2014;32:3021-32.
Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworsak MN, Adachi S, Bont ED, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012;120:3187–205.
Huang LB, Guan XQ, Zhang YC, Zhang XL, Ke ZY, Luo XQ. Current status of diagnosis and prognosis of infant acute leukemia in China: infant acute leukemia in China. Pediatr Blood Cancer 2009;53:973–7.
Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, et al. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984–2001: a report from the children’s oncology group. Leukemia 2010;24:355–70.
Dreyer ZE, Hilden JM, Jones TL, Devidas M, Winick NJ, Willman CL, et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). Pediatr Blood Cancer 2015;62:419–26.
Yaman-Bajin İ, Aytaç S, Kuşkonmaz B, Uçkan-Çetinkaya D, Ünal Ş, Gümrük F, et al. Infant lymphoblastic leukemia: a single centers 10 year experience. Turk J Pediatr 2019;61:325.
Pieters R, Schrappe M, Lorenzo PD, Hann I, Rossi GD, Felice M, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. Lancet 2007;370:240-50.
Hilden JM. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood 2006;108:441–51.
Chen SH, Yang CP, Hung IJ, Jaing TH, Shih LY, Tsai MH. Clinical features, molecular diagnosis, and treatment outcome of infants with leukemia in Taiwan: infant leukemia in Taiwan. Pediatr Blood Cancer 2010;55:1264–71.
Biondi A, Rizzari C, Valsecchi MG, Lorenzo PD, Aricò M, Basso G, et al. Role of treatment intensification in infants with acute lymphoblastic leukemia: results of two consecutive AIEOP studies. Haematologica 2006;91:534-7.
Webb DKH, Harrison G, Stevens RF, Gibson BG, Hann IM, Wheatley K. Relationships between age at diagnosis, clinical features, and outcome of therapy in children treated in the Medical Research Council AML 10 and 12 trials for acute myeloid leukemia. Blood 2001;98:1714–20.
Cherkaoui S, Bendari M, Madani A, Quessar A, Benchekroun. Acute megakaryoblastic leukemia in children: diagnosis and management challenges in resource-poor countries. Open Cancer J 2014;7:7–10.
Quintana J, Advis P, Becker A, Beresi V, Campbell M, Vinés EF, et al. Acute myelogenous leukemia in Chile PINDA protocols 87 and 92 results. Leukemia 2005;19:2143–6.
Lie SO, Abrahamsson J, Clausen N, Forestier E, Hasle H, Hovi L, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down’s syndrome: results of NOPHO-AML trials. Br J Haematol 2003;122:217–25.
Woods WG. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission: a report from the Children’s Cancer Group. Blood 2001;97:56–62.
Songthawee N, Chavananon S, Sripornsawan P, McNeil E, Chotsampancharoen T. Prevalence and risk factors of disseminated intravascular coagulation in childhood acute lymphoblastic leukemia. Pediatr Res 2023;94:588–93.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.